Controlled Released Drug Delivery Market by Product (Wurster Technique, Coacervation, Micro Encapsulation, Implants, Transdermal Targeted Delivery, and Others); Release mechanism (Polymer Based Systems, Micro Reservoir Partition Controlled Drug Delivery Systems, Feedback Regulated Drug Delivery Systems, Activation-modulated Drug Delivery Systems, and Chemically Activated); Application (Metered Dose Inhalers, Injectable, Transdermal, and Ocular Patches, Infusion Pumps, Oral Controlled-drug Delivery Systems, and Drug Eluting Stents): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026806 | Pages: 100 | Industry: Medical Device | Date: Oct 2022 | Type: Global

The market crossed the US$ 53.41 billion mark in 2022 and is expected to hit US$ 120.68 billion by 2030, recording a CAGR of 10.7% during the forecast period.

The controlled release drug delivery market has been significantly growing with the increasing geriatric population across the world.

Within the report, the market is segmented into product type, release mechanism, end-user, and geography. Based on product type, the market is segmented into Wurster Technique, Coacervation, Micro Encapsulation, Implants, Transdermal, Targeted Delivery, and Others. In 2022, the targeted therapy segment held the largest share of the market. Targeted delivery allows medications to be placed away from areas where they can cause drug toxicity and offers the intended site of action. It is a frequently selected drug delivery technology because these systems boost bioavailability and localize the medications which improve absorption, reduce fluctuations in circulating drug levels and lower the risk of side effects.

On the basis of application, the market is segmented into polymer-based systems, micro reservoir partition controlled drug delivery systems, feedback regulated drug delivery systems, activation-modulated drug delivery systems, and chemically activated. In terms of end-user, the market is classified into metered dose inhalers, injectable, transdermal, and ocular patches, infusion pumps, oral controlled-drug delivery systems, and drug-eluting stents. Geographically, the market is segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

 

The Rising Demand for Control Release Drug Administration  is a Major Factor in Accelerating The Market Growth of Medical Tubing

Control release drug administration allows a large decrease in dose and dosing frequency, minimizes aberrant variation in plasma drug level, increased efficacy boosts patient compliance, and provides uniform medication effects. The controlled release drug delivery system achieves a prolonged therapeutic effect in comparison to the standard delivery method because they distribute medication to the target site had predetermined times with predictable drug release kinetics as a result of the controlled release delivery system additional advantages their uses anticipated to grow significantly during the forecast period. In addition, the increasing geriatric population followed by a large patient base is one of the major factors assisting in driving the growth of the market.

Rising Technological Advancements are the Major Factor in Accelerating Market Growth in Future

Technological advancement will play a major role and will create huge opportunities for the growth of the controlled-release drug delivery systems market over the forecast period. Technology such as the microencapsulation market is anticipated to expand because of the growing desire to extend the shelf life and achieve controlled medications that release highly complex unstable compounds such as proteins vitamins and antioxidants. for instance, vitamin A has poor chemical stability and water solubility; nevertheless when it is microencapsulated the product shelf life rises, contributing to the control of drug release.

Recent Strategic Developments in the Controlled Released Drug Delivery Market.

The controlled release drug delivery market has undergone several significant developments, and a few of these have been mentioned below:

  • In July 2021, Johnson & Johnson received FDA approval for DARZALEX (daratumumab), a subcutaneous formulation that reduces the treatment time for multiple myeloma indications.
  • In December 2020, Pfizer, Inc. received FDA approval for BRAFTOVI (encorafenib) plus combination with cetuximab for the treatment of patients with brafv600e-mutant metastatic colorectal cancer (CRC) who have undergone prior therapy.
  • In November 2020, GlaxoSmithKline plc partnered with IDEAYA to enter the field of Synthetic Lethality, an emerging field in oncology; programs MAT2A, Pol Theta, and Werner Helicase programs, which are part of it, are projected to reach clinical trials in the next three years.

The controlled release drug delivery market is driven by several players by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Orbis Biosciences, Inc.; Merck and Co., Inc.; Alkermes plc; Johnson and Johnson; Coating Place, Inc.; Corium International, Inc.; Depomed, Inc.; Pfizer, Inc.; Aradigm Corporation; Capsugel among others are among the prominent players operating in the market.

The target audience for the report:

  • Compounding Pharmacies
  • Active ingredient distributor and retailer
  • Medicine Manufacturer
  • Government bodies, such as regulating authorities and policymakers
  • Venture capitalists, private equity firms, and start-up companies
  • Central Laboratory, Hospitals, and Clinics
  • Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented on the basis of:

  • Technology Type:
    • Wurster Technique
    • Coacervation
    • Micro Encapsulation
    • Implants
    • TransdermalTargeted Delivery
    • Others (Microelectromechanical Technology, Liposomes)
  • Release Mechanism
  • Polymer-Baseded Systems
  • Micro Reservoir Partition Controlled Drug Delivery Systems
  • Feedback Regulated Drug Delivery Systems
  • Activation-modulated Drug Delivery Systems
    • Osmotic Pressure Activated
    • Hydrodynamic Pressure Activated
    • Vapor Pressure Activated
    • Mechanically Activated
    • Magnetically Activated
  • Chemically Activated
    • pH Activated
    • Hydrolysis Activated
    • Enzyme Activated
  • Application
  • Metered Dose Inhalers
  • Injectable
  • Transdermal and Ocular Patches
  • Infusion Pumps
  • Oral Controlled-drug delivery Systems
  • Drug Eluting Stents
  • Region:
  • North America
  • Europe
  • Asia Pacific
  • South & Central America
  • Middle East & Africa
  • Companies profiled:
  • Orbis Biosciences, Inc.
  • Merck and Co., Inc.
  • Alkermes plc
  • Johnson and Johnson
  • Coating Place, Inc.
  • Corium International, Inc.
  • Depomed, Inc.
  • Pfizer, Inc.
  • Aradigm Corporation
  • Capsugel
  • Others

The List of Companies:
- Orbis Biosciences, Inc.
- Merck and Co., Inc.
- Alkermes plc
- Johnson and Johnson
- Coating Place, Inc.
- Corium International, Inc.
- Depomed, Inc.
- Pfizer, Inc.
- Aradigm Corporation
- Capsugel
- Others

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$2000
Site License
$3000
Enterprise License
$4000